Work

Abstract A254: A phase 1 safety and pharmacokinetic (PK) study of PI3K/TORC1/TORC2 inhibitor, XL765 (SAR245409), in combination with erlotinib in patients (pts) with advanced solid tumors

Year: 2009

Type: conference-abstract

Source: Molecular Cancer Therapeutics

DOI: 10.1158/1535-7163.targ-09-a254

Authors: Pasi A. Janne, Enriqueta Felip, Susana Cedrés, Steven J. Cohen, Jeffrey A. Engelman, Joan Lucca, Pablo Martínez, Margaret von Mehren, Steven B. Gendreau, Katherine K. Lara, Jean-Francois Martini, Roger B. Cohen

Institutions: Dana-Farber Cancer Institute, Vall d'Hebron Hospital Universitari, Fox Chase Cancer Center, Massachusetts General Hospital, Exelixis (United States)

Language: English

Topic: PI3K/AKT/mTOR signaling in cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2000865149

Cites:

Cited by: 2

Related to: 10